Pharmaceuticals
VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update
* Strong balance sheet with approximately $27.9 million in cash and cash equivalents * Strengthened the Company's veterinary leadership team to drive commercial focus * Expanded the Company's intellectual property portfolio * Published two clinical papers * Continued focus on, and made s...
2021-08-12 04:10
25473
ImmVira's MVR-T3011 IV Completed First Dosing for Intravenous Administration in a U.S. Phase I Clinical Trial
SHENZHEN, China, Aug. 10, 2021 /PRNewswire/ -- ImmVira announced that it has initiated its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011). The first patient has been dosed, receiving MVR-T3011 intravenous (IV) administration in the U.S. onAugust 10, 2021. The Phase I clin...
2021-08-11 10:45
1820
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP in China
BEIJING, Aug. 10, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) for startin...
2021-08-11 08:00
18032
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
HONG KONG, Aug. 5, 2021 /PRNewswire/ -- Akeso, Inc. (9926.HK, the "Company" or "Akeso") announced that the anti PD-1 monoclonal antibody drugPenpulimab monoclonal antibody injection co-developed by the Company with Sino Biopharmaceutical Limited (stock code: 1177.HK), has obtained marketing appr...
2021-08-06 09:39
29188
China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval
HAIKOU, China, Aug. 5, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the result...
2021-08-05 21:00
27306
Berry Oncology Completes Series B1 Funding, Attracting Most Venture Capital to Date in Early Cancer Screening Sector
BEIJING, Aug. 5, 2021 /PRNewswire/ -- Berry Oncology Corporation, a member company ofChina's leading early cancer screening firm Berry Genomics, yesterday on its 4th anniversary, announced the completion of a US$99.15 million Series B1 financing round. This brings the total capital raised by the ...
2021-08-05 21:00
2619
Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model
SYDNEY, Aug. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBP...
2021-08-05 18:00
2054
Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®
SEOUL, South Korea, Aug. 3, 2021 /PRNewswire/ -- Yuyu Pharma, a pharmaceutical company based in Korea, and Novartis Korea announced today that the companies have entered into an agreement in which Yuyu will have exclusive distribution rights for the following prescription medicines in Korea: Lami...
2021-08-03 21:00
2703
111, Inc. Enters into Strategic Cooperation Agreement with Zelgen to Develop a New Management Platform for Liver Cancer Patients in China
SHANGHAI, Aug. 3, 2021 /PRNewswire/ – 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced a strategic cooperation agreement with Suzhou Zelgen ...
2021-08-03 20:00
8426
TCM Lianhua Qingwen shows stable in vitro antiviral effect on the Delta variant: Expert
GUANGZHOU, China, Aug. 3, 2021 /PRNewswire/ -- The latest research findings from the team of Professor Yang Zifeng from the State Key Laboratory of Respiratory Disease inGuangzhou, China, have showed that Chinese medicine Lianhua Qingwen has an effective inhibitory action on the Delta variant of ...
2021-08-03 15:27
3146
Bionomics Announces Plans to Conduct U.S. Initial Public Offering
ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United ...
2021-08-02 18:00
14622
LISCure Biosciences Announces Know-How License Agreement and Stock Purchase Agreement with Mayo Clinic
SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered into a know-how license and development collaboration agreement, and stock purchase agreement with Mayo Clinic to advance LISCure's microbiome therapeutics in non-alcoholic steatohepatitis (NASH). ...
2021-08-02 11:11
1887
Appendix 4C - Q4 FY21 Quarterly Cash Flow Report
Highlights: * Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial * Publication in Movement Disorders demonstrates that ATH434 reduces α–synuclein related neurodegeneration in MSA animal model * Presents to MST Access Australian Micro & Small Caps Conference ...
2021-07-30 21:05
15656
China Jo-Jo Drugstores Completes Redomiciliation Merger
HANGZHOU, China, July 30, 2021 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that th...
2021-07-30 21:00
15608
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
* Planning underway for a Phase 1 Trial to assess new immunotherapy aimed at stimulating the innate immune system to clear beta amyloid protein plaques in Alzheimer's Disease SHANGHAI and GAITHERSBURG, Md., July 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage bio...
2021-07-30 20:00
9326
I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million
SHANGHAI and GAITHERSBURG, Md., July 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of Directors (the "Board") has authorized...
2021-07-29 20:00
7825
HanAll Biopharma Reports Second Quarter 2021 Results
* Q2'21 sales of KRW 23.4 billion increased 4% from the same period last year * Q2'21 operating profit of KRW 1.6 billion fell slightly by 3% compared to Q2'20 * H1'21 sales of KRW 51.2 billion and operating profit of 6.3 billion grew by 15% and 56% YoY [Business Performance and Financial St...
2021-07-29 18:44
11494
Daewoong Pharmaceutical Announces Camostat Achieving 50% Faster Recovery Time for Mild COVID-19 Patients Over Age of 50 in Topline Results from Phase 2B Clinical Trial
- Improvement of symptoms such as cough and dyspnea in mild patients over age 50 was reported to be as twice as fast and statistically significant in the treatment group (4 days) compared to the placebo control group (9 days). - Development is underway for potential combination therapies and nove...
2021-07-29 18:00
2034
Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial
SYDNEY, July 28, 2021 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has commenced its64/67Cu SAR-bisPSMA theranostic clinical trial in patients with metastatic castrate resistant pr...
2021-07-28 21:08
2288
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
* Efineptakin alfa in combination with pembrolizumab induced 27.8% ORR in metastatic TNBC patients in a phase1b/2 trial in South Korea * Efineptakin alfa in patients with GBM showed a 83.3% survival ratio over one year in a phase 1 trial in the U.S. SHANGHAI and GAITHERSBURG, Md., July 28, 20...
2021-07-28 19:15
4823
Week's Top Stories
Most Reposted
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 299 media titles]
2026-06-04 23:55
Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 291 media titles]
2026-06-05 19:08
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 291 media titles]
2026-06-05 15:00Pudu Robotics and Shenzhen CTID Co. Ltd Launch the World's First Full-Scenario Robot-Serviced Hotel Project
[Picked up by 275 media titles]
2026-06-01 18:00FPT and NVIDIA Collaborate to Release the Nemotron Personas Vietnam Datasets
[Picked up by 275 media titles]
2026-06-05 17:34
Most Read
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
2026-05-30 11:58
8620
XCMG Secures Over $1 Billion in Orders at 8th International Customer Festival, Expanding Global Partnerships
2026-05-30 00:30
6953
WePlay Korea's 4th Anniversary Celebration Kicks Off, Joining Hands with "Hello Panda-哈啰潘达" to Create Fu Bao Themed Space Decorations
2026-06-01 12:00
6147
NYSE Content Update: FedEx Freight to List on the NYSE + Join S&P 500
2026-06-01 21:32
5947
